Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase II Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours

NCT01876771 is registered in ClinicalTrials.gov with AHS Cancer Control Alberta as lead sponsor.

NCT NCT01876771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01876771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase II Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours
Lead sponsor
AHS Cancer Control Alberta
Phase
Phase 2
Overall status
Suspended
Start date
April 29, 2014
Completion date
December 31, 2042
Enrollment
413 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, neuroendocrine